Skip to main content
. 2022 Mar 25;11(4):1443–1457. doi: 10.1007/s40121-022-00607-x

Fig. 3.

Fig. 3

Two-way sensitivity analysis: relationship between cost-effectiveness and clinical efficacy of IMI/REL relative to CMS + IMI. CI confidence interval, IMI/REL imipenem/cilastatin/relebactam, CMS + IMI colistimethate sodium plus imipenem/cilastatin